Share

Sartorius Stedim Biotech is currently covered by 16 sell-side analysts. The following list shows their latest recommendations for Sartorius Stedim Biotech shares.

Disclaimer

_{The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.}

_{Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.}

Sartorius Stedim Biotech S.A.’s issued capital amounted to €18.4 million as of February 28, 2022, and was divided into 92,180,190 shares, each with a calculated par value of €0.20. As some of the shares convey double voting rights, there were a total of 160,522,434 voting rights as of the reporting date.

As of February 28, 2022, Sartorius AG holds 73.6% of the share capital and 84.6% of the outstanding voting rights. The remaining 26.4% of the shares are in free float; corresponding to 15.4% of the outstanding voting rights.